Navigation Links
Novel compounds show promise as safer, more potent insecticides

Research teams at Nihon Nohyaku Co., Ltd., Bayer CropScience and DuPont have developed two new classes of broad-spectrum insecticides that show promise as a safer and more effective way to fight pest insects that damage food crops. The insecticides, which represent the first synthetic compounds designed to activate a novel insecticide target called the ryanodine receptor, may also help tackle the growing problem of insecticide resistance, the researchers say. They described their studies today at the 230th national meeting of the American Chemical Society, the world’s largest scientific society.

Many of the most widely used insecticides today act on only a handful of exploited targets, including the organophosphates, which block acetylcholinesterase, an enzyme that helps control nerve activity. Some experts are concerned that these older, less-selective insecticides could pose heath risks and there’s a growing effort underway to find safer replacements.

Targeting the ryanodine receptor may offer a promising alternative, researchers say. Ryanodine, a natural alkaloid discovered years ago in a species of tropical plant, has been used to study muscle physiology in a wide variety of organisms, including insects and mammals. Ryanodine receptors regulate muscle and nerve activities by modifying levels of internal calcium in these cells. These receptors exist in both mammals and insects but have distinct differences. Researchers have known that ryanodine itself has insecticidal properties, but no synthetic molecules had previously been identified that potently and selectively target these receptors in insects, until now.

Nihon Nohyaku Co., Ltd., based in Japan, and Bayer CropScience AG in Germany have jointly developed Flubendiamide, the first example of the phthalic acid diamides, a novel class of insecticides that activate the ryanodine receptor. The insecticide is highly effective against many different species of caterpillars, says Masanori Tohni shi, a senior research scientist at Nihon Nohyaku. In early tests, the compound showed high activity against the tobacco budworm (Heliothis virescens), which is known to cause serious damage to cotton, tobacco and other crops, the researchers say. The compound did not have any measurable effect on mammalian ryanodine receptors, according to Peter Lümmen, Ph.D., a research scientist at Bayer CropScience.

DuPont, based in Wilmington, Del., is developing another group of compounds that target the ryanodine receptor. Called anthranilic diamides, these novel compounds show excellent control of pest insects with exceptional mammalian safety, according to the researchers. They were the first to demonstrate the mode of action of these ryanodine receptor-active molecules, says Daniel Cordova, a researcher at DuPont Crop Protection.

Both classes of compounds are believed to have high potency, the researchers say, although they are structurally different. Both insecticides are still in developmental stages.

The research team at DuPont says they have cloned ryanodine receptors from several insect species and that these receptors may help provide a better understanding of their role in calcium signaling, which could lead to new insights into human diseases.

The American Chemical Society is a nonprofit organization, chartered by the U.S. Congress, with a multidisciplinary membership of more than 158,000 chemists and chemical engineers. It publishes numerous scientific journals and databases, convenes major research conferences and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.


'"/>

Source:American Chemical Society


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... PUNE, India , January 19, 2017 According ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market ... 9.6% from 2016 to 2022. In 2015, Asia-Pacific dominated ... both public and private sectors. Continue Reading ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems ... Nipro will receive exclusive marketing and sales rights for all non-OEM Transonic products in ... patients in Japan, the new Nipro - Transonic JV is a natural next step ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... 2017 Aratana Therapeutics, Inc. (NASDAQ: ... licensing, development and commercialization of innovative biopharmaceutical products for ... in North America 2016. ... based on the FDA approval of three innovative therapeutics ... (capromorelin oral solution) and NOCITA ® (bupivacaine ...
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies to join the ... Vironika, a spin out from The Wistar Institute, and Sanguis, launched by a trio ... Market Street. , Vironika is developing a treatment for a chronic viral infection ...
Breaking Biology Technology: